Skip to main content
GLUE
NASDAQ Life Sciences

Monte Rosa Therapeutics第四季度合作收入暴跌95%至278万美元

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
9
Price
$15.87
Mkt Cap
$1.247B
52W Low
$3.5
52W High
$25.77
Market data snapshot near publication time

summarizeSummary

Monte Rosa Therapeutics报告称，其第四季度合作收入大幅下滑，暴跌至278万美元，相比之下，同期前一年的合作收入为6060万美元。这代表着该生命科学公司的一项关键收入来源大幅减少95%。虽然该公司最近宣布了一项积极的临床供应协议，但过去合作收入的此次急剧下滑是一个重大的负面发展，可能会引发人们对公司财务轨迹和未来合作潜力的担忧。交易者将密切关注完整的财务报告，以了解此次下滑的根本原因和任何更新的财务指导。

在该公告发布时，GLUE的交易价格为$15.87，交易所为NASDAQ，所属行业为Life Sciences，市值约为$12.5亿。 52周交易区间为$3.50至$25.77。 这则新闻被评估为消极市场情绪，重要性评分为9/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed GLUE - Latest Insights

GLUE
Mar 17, 2026, 7:14 AM EDT
Filing Type: 10-K
Importance Score:
9
Monte Rosa Therapeutics Secures Substantial Capital, Extends Runway to 2029, and Advances Clinical Pipeline
Sentiment: Positive
View Wiseek Article
GLUE
Mar 17, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Monte Rosa Therapeutics Secures $345M Financing, Extends Cash Runway into 2029 Amidst Pipeline Advancements
Sentiment: Positive
View Wiseek Article
GLUE
Mar 17, 2026, 7:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Monte Rosa Therapeutics' Q4 Collaboration Revenue Plummets 95% to $2.78M
Sentiment: Negative
View Wiseek Article
GLUE
Mar 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Monte Rosa's MRT-2359 Enters Phase 2 for Prostate Cancer with J&J Apalutamide Supply
Sentiment: Positive
View Wiseek Article
GLUE
Feb 11, 2026, 4:36 PM EST
Filing Type: S-3ASR
Importance Score:
8
Registers New $100M At-The-Market Offering for Capital Raises
Sentiment: Negative
View Wiseek Article
GLUE
Jan 09, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Monte Rosa Therapeutics Prices $300M Public Offering, Extending Cash Runway into 2029
Sentiment: Neutral
View Wiseek Article
GLUE
Jan 09, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
Monte Rosa Therapeutics Announces $300M Public Offering to Fund Clinical Programs and Extend Cash Runway
Sentiment: Neutral
View Wiseek Article
GLUE
Jan 09, 2026, 4:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Versant Funds Significantly Reduce Stake in Monte Rosa Therapeutics
Sentiment: Negative
View Wiseek Article
GLUE
Jan 07, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Monte Rosa Therapeutics Terminates At-The-Market Equity Offering Program
Sentiment: Positive
View Wiseek Article
GLUE
Jan 07, 2026, 4:07 PM EST
Filing Type: 424B5
Importance Score:
8
Monte Rosa Therapeutics Announces $200M Offering and Positive Phase 1 Data for MRT-8102
Sentiment: Neutral
View Wiseek Article